Loading…
MANNITOL is a brand name for Mannitol. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For use as an osmotic diuretic alone or to supplement the action of other diuretics in order to promote renal function, including the assisted elimination of drugs such as aspirin and barbiturates.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults and Children The volume, strength and rate of infusion of mannitol solutions given in intravenous will depend upon the requirements of the patient and the judgement of the physician. A dosage of 200 g daily by intravenous infusion should not be exceeded.
Elderly Elderly patients are more susceptible to the adverse effects associated with mannitol. This is due to diminished renal and cardiac reserves. Elderly patients should therefore be given a test dose as described below for patients with renal impairment.
Renal Impairment Patients with impaired renal function should be given a test dose of 200 mg per kilogram body weight administered over five minutes and if 40 ml or more of urine is produced in an hour, mannitol may then be given in therapeutic doses.
Method of administration Intravenous use.
Rapid intravenous infusion of mannitol may produce headache, chills or chest pain. It may also depress respiration by altering the acid base and electrolyte balance of the body fluids. Convulsions have been known in, patients administered excessive doses of mannitol solutions.
Other side effects reported may be associated with hypersensitivity reactions. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows the continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard.
Solutions of mannitol given in intravenous infusion should be administered slowly and should not be mixed with blood in transfusion apparatus. All patients given mannitol should be observed for signs of fluid and electrolyte imbalance.
If renal flow is inadequate, water intoxication is likely in patients receiving intravenous mannitol, therefore its use in oedematous conditions associated with diminished cardiac reserve should only be considered if the advantages outweigh the risks.
The label states:
To retard crystallisation store at 20°- 30°. Carefully examine the solution for crystals immediately before use. If necessary redissolve by raising the temperature to 60°, maintaining it at this temperature, and shaking occasionally until the crystals have redissolved.
Cool to blood heat before use.
1. Mannitol is contraindicated in, patients with abnormal capillary fragility, pulmonary congestion or pulmonary oedema, intracranial bleeding, congestive heart failure and renal failure unless a test dose has produced a diuretic response.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Mannitol in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.